A share price of Nuvation Bio Inc [NUVB] is currently trading at $1.80, up 8.43%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The NUVB shares have gain 2.27% over the last week, with a monthly amount drifted -10.89%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Nuvation Bio Inc [NYSE: NUVB] stock has seen the most recent analyst activity on March 27, 2024, when Jefferies upgraded its rating to a Buy and also boosted its price target to $10 from $1.40. Previously, BTIG Research upgraded its rating to Buy on March 26, 2024, and kept the price target unchanged to $5. On January 06, 2023, downgrade downgraded it’s rating to Hold and revised its price target to $2 on the stock. BTIG Research downgraded its rating to a Neutral. BMO Capital Markets downgraded its rating to a Market Perform and reduced its price target to $2.50 on August 02, 2022. H.C. Wainwright started tracking with a Buy rating for this stock on May 04, 2022, and assigned it a price target of $14.
Nuvation Bio Inc experienced fluctuations in its stock price throughout the past year between $1.57 and $3.97. Currently, Wall Street analysts expect the stock to reach $6.75 within the next 12 months. Nuvation Bio Inc [NYSE: NUVB] shares were valued at $1.80 at the most recent close of the market. An investor can expect a potential return of 275.0% based on the average NUVB price forecast.
Analyzing the NUVB fundamentals
Gross Profit Margin for this corporation currently stands at 0.06% with Operating Profit Margin at -21.28%, Pretax Profit Margin comes in at -72.14%, and Net Profit Margin reading is -72.14%. To continue investigating profitability, this company’s Return on Assets is posted at -1.05, Equity is -1.25 and Total Capital is -0.35. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.6167 points at the first support level, and at 1.4333 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.9067, and for the 2nd resistance point, it is at 2.0133.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Nuvation Bio Inc [NYSE:NUVB] is 9.04. Also, the Quick Ratio is 9.04, while the Cash Ratio stands at 0.61. Considering the valuation of this stock, the price to sales ratio is 77.46, the price to book ratio is 1.31.
Transactions by insiders
Recent insider trading involved Mashal Robert, Director, that happened on Apr 01 ’25 when 100000.0 shares were purchased. CEO, ANHEART THERAPEUTICS LTD., Wang Junyuan Jerry completed a deal on Nov 11 ’24 to sell 56361.0 shares. Meanwhile, Director Mashal Robert bought 100000.0 shares on Oct 08 ’24.
